AFYX-002

AFYX-002 is a small molecule substitution therapy being developed by AFYX Therapeutics for the treatment of addiction. The program leverages the company's proprietary Rivelin mucoadhesive patch technology, which is designed to adhere to mucosal membranes (such as the buccal mucosa) to provide sustained and controlled delivery of the active pharmaceutical ingredient. As a substitution therapy, AFYX-002 is intended to mimic the effects of an abused substance to alleviate withdrawal symptoms and reduce cravings, thereby facilitating the management of substance use disorders. While the specific active ingredient has not been explicitly confirmed in public pipeline disclosures, the delivery method is engineered to improve bioavailability and patient compliance compared to traditional oral or transdermal routes. Development status reports for this asset are inconsistent, with some sources indicating it is in preclinical stages while others suggest it is marketed or approved.